Kite Pharma, Inc. (KITE)

Oncology Corporate Profile

Stock Performance

46.5000
-0.8200

HQ Location

2225 Colorado Avenue
Santa Monica, CA 90404

Company Description

Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapeutic products, with a major focus on eACT therapy designed at restoring the patient's immune system to recognize and eradicate tumors. In partnership with the NCI Surgery Branch, Kite is advancing a pipeline of proprietary eACT product candidates, both CAR and TCR products, directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are designed to provide significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments.

Website: http://www.kitepharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
axicabtagene ciloleucelchimeric antigen receptor (CAR)®Diffuse large B-cell Lymphoma (DLBCL)II
KTE-C19chimeric antigen receptorMantle Cell Lymphoma (MCL)II
axicabtagene ciloleucelchimeric antigen receptor (CAR)®Primary mediastinal b-cell Lymphoma (PMBCL)II
axicabtagene ciloleucelchimeric antigen receptor (CAR)®Transformed follicular Lymphoma (TFL)II
KTE-C19chimeric antigen receptorAcute Lymphoblastic LeukemiaI
KTE-C19chimeric antigen receptorB-cell LymphomaI
HPV-16 E6 & E7t-cell therapyCervical cancerINCI
KTE-C19chimeric antigen receptorDiffuse large B-cell Lymphoma (DLBCL)I
EGFRvIII CARchimeric antigen receptorGlioblastoma Multiforme (GBM)I
HPV-16 E6 & E7t-cell therapyHead & Neck cancerINCI
KTE-C19chimeric antigen receptor2nd line Diffuse large B-cell Lymphoma (DLBCL)Preclinical
KTE-C19chimeric antigen receptorAcute Myelogenous Leukemia (AML)Preclinical
KTE-C19chimeric antigen receptorChronic Lymphocytic Leukemia (CLL)Preclinical
KITE-585anti-B cell maturation antigen (BCMA) Multiple MyelomaPreclinical
KTE-C19chimeric antigen receptorNon-Hodgkin's Lymphoma (NHL)Preclinical
eACTt-cell therapyVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.kitepharma.com

Recent News Headlines

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/15/2017 06:18 pm

5/15/2017 06:18 pm

5/15/2017 06:18 pm

5/15/2017 06:18 pm

5/15/2017 12:18 pm

5/14/2017 06:18 am

5/14/2017 06:18 am

5/14/2017 06:18 am

5/14/2017 06:18 am

5/14/2017 06:18 am

5/11/2017 12:18 pm

5/10/2017 06:18 am

5/9/2017 12:18 pm

5/8/2017 06:18 pm

5/8/2017 12:18 pm

5/8/2017 12:18 pm